Steven Gans

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Bonne Biesma, David F. Heigener et al. · Journal of Clinical Oncology · 2012 · 257 citations · Full text

Medicine, Oncology, Pharmacology +16

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 175 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study

Claus Vogelmeier, Péter Kardos, Sergio Harari et al. · Respiratory Medicine · 2008 · 171 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9